Literature DB >> 29741800

EBI2 in splenic and local immune responses and in autoimmunity.

L Barington1, F Wanke2, K Niss Arfelt1, P J Holst3, F C Kurschus2, M M Rosenkilde1.   

Abstract

The seven transmembrane G protein-coupled receptor EBV-induced gene 2 (EBI2), also known as GPR183, is expressed in particular in immune cells. Activated by its endogenous ligands, which are a group of oxysterols, it functions as a chemo-attractant receptor, mediating cell migration. In coordination with other receptors, EBI2 plays important roles in controlling the migration of immune cells during the course of a T-dependent Ab response in the spleen. In recent years, it has become clear that EBI2 also has other roles to play in the immune system. Thus, EBI2 seems to be involved in innate immune responses, such as those mediated by TLR signaling, and it has been implicated in regional immune responses, including immune responses in the CNS. In this review, we describe the functions of EBI2 in B cells, T cells, and dendritic cells during the course of a T-dependent Ab response in the spleen. Furthermore, we review the existing evidence supporting a role for EBI2 in local immune responses and in autoimmune diseases, with a special focus on immune responses in the CNS. Finally, we discuss which type of role EBI2 may play in autoimmune diseases, and we give our opinion about the paths of future research in EBI2. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  GPCR; GPR183; migration; oxysterol

Mesh:

Substances:

Year:  2018        PMID: 29741800     DOI: 10.1002/JLB.2VMR1217-510R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Characterization of lncRNA-Based ceRNA Network and Potential Prognostic Hub Genes for Sepsis.

Authors:  Yiqing Tong; Yanping Yang; Qiming Feng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-21       Impact factor: 2.650

Review 2.  Effects of Oxysterols on Immune Cells and Related Diseases.

Authors:  Fábio Alessandro de Freitas; Débora Levy; Cadiele Oliana Reichert; Edecio Cunha-Neto; Jorge Kalil; Sérgio Paulo Bydlowski
Journal:  Cells       Date:  2022-04-07       Impact factor: 7.666

3.  GPR183 Is Dispensable for B1 Cell Accumulation and Function, but Affects B2 Cell Abundance, in the Omentum and Peritoneal Cavity.

Authors:  Line Barington; Liv von Voss Christensen; Kristian Kåber Pedersen; Kristine Niss Arfelt; Martin Roumain; Kristian Høj Reveles Jensen; Viktoria Madeline Skovgaard Kjær; Viktorija Daugvilaite; John F Kearney; Jan Pravsgaard Christensen; Gertrud Malene Hjortø; Giulio G Muccioli; Peter Johannes Holst; Mette Marie Rosenkilde
Journal:  Cells       Date:  2022-01-31       Impact factor: 6.600

4.  Rapid GPR183-mediated recruitment of eosinophils to the lung after Mycobacterium tuberculosis infection.

Authors:  Andrea C Bohrer; Ehydel Castro; Claire E Tocheny; Maike Assmann; Benjamin Schwarz; Eric Bohrnsen; Michelle A Makiya; Fanny Legrand; Kerry L Hilligan; Paul J Baker; Flor Torres-Juarez; Zhidong Hu; Hui Ma; Lin Wang; Liangfei Niu; Zilu Wen; Sang H Lee; Olena Kamenyeva; Keith D Kauffman; Michele Donato; Alan Sher; Daniel L Barber; Laura E Via; Thomas J Scriba; Purvesh Khatri; Yanzheng Song; Ka-Wing Wong; Catharine M Bosio; Amy D Klion; Katrin D Mayer-Barber
Journal:  Cell Rep       Date:  2022-07-26       Impact factor: 9.995

5.  Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.

Authors:  Ming Xu; Yu Li; Wenhui Li; Qiuyang Zhao; Qiulei Zhang; Kehao Le; Ziwei Huang; Pengfei Yi
Journal:  Front Med (Lausanne)       Date:  2020-03-05

Review 6.  Cholesterol metabolism: from lipidomics to immunology.

Authors:  William J Griffiths; Yuqin Wang
Journal:  J Lipid Res       Date:  2021-12-22       Impact factor: 5.922

7.  Discovery of GPR183 Agonists Based on an Antagonist Scaffold.

Authors:  Viktoria M S Kjaer; Loukas Ieremias; Viktorija Daugvilaite; Michael Lückmann; Thomas M Frimurer; Trond Ulven; Mette M Rosenkilde; Jon Våbenø
Journal:  ChemMedChem       Date:  2021-08-03       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.